Phase II Study of ASP3550 - A Maintenance-dose Finding Study for Periodic Dosage Regimen in Patients With Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 May 2017
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 10 Jun 2017 Biomarkers information updated
- 19 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Dec 2010 New trial record